Dr. Daniela Moran, MD
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 119
Licensed in Texas since 1998, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
TX license K6851 (first issued 1998; active) -
Pulmonary Disease Physician
TX license K6851 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Houston Methodist Hospital Houston, TX
Medical groups
- Tmh Physician Associates PLLC (1,690 clinicians)
- Houston Methodist Specialty Physicians (1,528 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 119
- Services billed
- 418
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 419 | 134 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 54 | 42 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 37 | 31 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 24 | 17 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 15 | 14 |
| Insertion of artery tube for blood sampling or infusion through skin | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $216 in total to this clinician.
| La Jolla Pharmaceutical Company | $110 |
|---|---|
| Merck Sharp & Dohme LLC | $106 |
| Food and Beverage | $216 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $42,119 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.